Biosimilars Versus Generics: Differences in the Regulatory Review Process

Article

Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, discusses the regulatory review process for biosimilars and how it differs from the generic approval process.

At the American Society for Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, discussed the regulatory review process for biosimilars and how it differs from the generic review process.

Related Videos
pain management palliative care/Image Credits: © Aleksej - stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
palliative and hospice care/ Image Credits: © David Pereiras - stock.adobe.com
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
multiple myeloma clinical trial/Image Credits: © Studio Romantic - stock.adobe.com
3d rendered illustration of lung cancer 3D illustration - Image credit:  appledesign | stock.adobe.com
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.